Logo image of EQ

EQUILLIUM INC (EQ) Stock Fundamental Analysis

NASDAQ:EQ - Nasdaq - US29446K1060 - Common Stock - Currency: USD

0.3851  0 (-0.05%)

After market: 0.3952 +0.01 (+2.62%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EQ. EQ was compared to 561 industry peers in the Biotechnology industry. The financial health of EQ is average, but there are quite some concerns on its profitability. EQ is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EQ has reported negative net income.
In the past year EQ has reported a negative cash flow from operations.
EQ had negative earnings in each of the past 5 years.
In the past 5 years EQ always reported negative operating cash flow.
EQ Yearly Net Income VS EBIT VS OCF VS FCFEQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

EQ has a better Return On Assets (-31.51%) than 64.53% of its industry peers.
EQ has a better Return On Equity (-42.32%) than 68.63% of its industry peers.
Industry RankSector Rank
ROA -31.51%
ROE -42.32%
ROIC N/A
ROA(3y)-45.84%
ROA(5y)-43.62%
ROE(3y)-98.95%
ROE(5y)-79.65%
ROIC(3y)N/A
ROIC(5y)N/A
EQ Yearly ROA, ROE, ROICEQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100 -150

1.3 Margins

EQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EQ Yearly Profit, Operating, Gross MarginsEQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

EQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EQ has more shares outstanding
Compared to 5 years ago, EQ has more shares outstanding
There is no outstanding debt for EQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EQ Yearly Shares OutstandingEQ Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EQ Yearly Total Debt VS Total AssetsEQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -7.92, we must say that EQ is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EQ (-7.92) is worse than 71.12% of its industry peers.
There is no outstanding debt for EQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.92
ROIC/WACCN/A
WACC10.1%
EQ Yearly LT Debt VS Equity VS FCFEQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 3.93 indicates that EQ has no problem at all paying its short term obligations.
EQ's Current ratio of 3.93 is in line compared to the rest of the industry. EQ outperforms 45.99% of its industry peers.
A Quick Ratio of 3.93 indicates that EQ has no problem at all paying its short term obligations.
EQ's Quick ratio of 3.93 is in line compared to the rest of the industry. EQ outperforms 47.77% of its industry peers.
Industry RankSector Rank
Current Ratio 3.93
Quick Ratio 3.93
EQ Yearly Current Assets VS Current LiabilitesEQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

EQ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.03%, which is quite impressive.
Looking at the last year, EQ shows a quite strong growth in Revenue. The Revenue has grown by 13.90% in the last year.
EPS 1Y (TTM)41.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-128.57%
Revenue 1Y (TTM)13.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-52.32%

3.2 Future

The Earnings Per Share is expected to grow by 11.60% on average over the next years. This is quite good.
EQ is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.44% yearly.
EPS Next Y-280.65%
EPS Next 2Y-120.94%
EPS Next 3Y-51.08%
EPS Next 5Y11.6%
Revenue Next Year-100%
Revenue Next 2Y-52.55%
Revenue Next 3Y12.09%
Revenue Next 5Y19.44%

3.3 Evolution

EQ Yearly Revenue VS EstimatesEQ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
EQ Yearly EPS VS EstimatesEQ Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EQ. In the last year negative earnings were reported.
Also next year EQ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EQ Price Earnings VS Forward Price EarningsEQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EQ Per share dataEQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

EQ's earnings are expected to decrease with -51.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-120.94%
EPS Next 3Y-51.08%

More info and screens

0

5. Dividend

5.1 Amount

EQ does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EQUILLIUM INC

NASDAQ:EQ (5/21/2025, 8:00:01 PM)

After market: 0.3952 +0.01 (+2.62%)

0.3851

0 (-0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08
Earnings (Next)N/A N/A
Inst Owners19.88%
Inst Owner Change-0.52%
Ins Owners24.39%
Ins Owner Change0%
Market Cap13.76M
Analysts42
Price Target1.02 (164.87%)
Short Float %0.63%
Short Ratio1.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)74.95%
Min EPS beat(2)49.89%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)75.93%
Min EPS beat(4)47.34%
Max EPS beat(4)106.47%
EPS beat(8)8
Avg EPS beat(8)62.92%
EPS beat(12)10
Avg EPS beat(12)73.84%
EPS beat(16)12
Avg EPS beat(16)55.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-75%
PT rev (3m)-75%
EPS NQ rev (1m)-28.85%
EPS NQ rev (3m)-11.67%
EPS NY rev (1m)-10.39%
EPS NY rev (3m)1.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS1.15
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.51%
ROE -42.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.84%
ROA(5y)-43.62%
ROE(3y)-98.95%
ROE(5y)-79.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.04%
Cap/Sales 0.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.93
Quick Ratio 3.93
Altman-Z -7.92
F-Score4
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)111.69%
Cap/Depr(5y)164.16%
Cap/Sales(3y)0.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-128.57%
EPS Next Y-280.65%
EPS Next 2Y-120.94%
EPS Next 3Y-51.08%
EPS Next 5Y11.6%
Revenue 1Y (TTM)13.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-52.32%
Revenue Next Year-100%
Revenue Next 2Y-52.55%
Revenue Next 3Y12.09%
Revenue Next 5Y19.44%
EBIT growth 1Y43.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.66%
OCF growth 3YN/A
OCF growth 5YN/A